acdbio.com · 545
ACDBio is a pioneering company specializing in In Situ Hybridization (ISH) technology, specifically RNA-ISH. With our innovative solutions, researchers can detect, localize, and quantify vector and therapeutic transgenes, visualize and quantify expression of multiple checkpoint and immune cell markers, and assess drug safety with unmatched sensitivity and specificity for any target in any tissue for any species. Our technology also allows for species-specific gene expression profiling of patient-derived xenograft tumors. In addition to providing advanced solutions for biomarker assays, we offer a wide range of products such as the RNAscope™ 2.5 HD Assay-Brown, RNAscope™ 2.5 HD Assay-Red, RNAscope™ HiPlex v2 Assay, and more. Visit our website to learn more about our cutting-edge technology and how it can benefit your research.
acdbio.com · years statistic
2009
| 1 | 0 |
| 2 | 0 |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| 6 | 0 |
| 7 | 0 |
| 8 | 1 |
| 9 | 0 |
| 10 | 0 |
| 11 | 0 |
| 12 | 0 |
2010
| 1 | 0 |
| 2 | 0 |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| 6 | 0 |
| 7 | 0 |
| 8 | 1 |
| 9 | 0 |
| 10 | 0 |
| 11 | 1 |
| 12 | 0 |
2011
| 1 | 0 |
| 2 | 2 |
| 3 | 0 |
| 4 | 1 |
| 5 | 0 |
| 6 | 0 |
| 7 | 0 |
| 8 | 0 |
| 9 | 3 |
| 10 | 1 |
| 11 | 1 |
| 12 | 1 |
2012
| 1 | 3 |
| 2 | 3 |
| 3 | 6 |
| 4 | 3 |
| 5 | 0 |
| 6 | 0 |
| 7 | 1 |
| 8 | 1 |
| 9 | 1 |
| 10 | 2 |
| 11 | 4 |
| 12 | 2 |
2013
| 1 | 3 |
| 2 | 0 |
| 3 | 0 |
| 4 | 0 |
| 5 | 1 |
| 6 | 0 |
| 7 | 0 |
| 8 | 1 |
| 9 | 1 |
| 10 | 0 |
| 11 | 3 |
| 12 | 0 |
2014
| 1 | 0 |
| 2 | 3 |
| 3 | 0 |
| 4 | 0 |
| 5 | 1 |
| 6 | 2 |
| 7 | 15 |
| 8 | 2 |
| 9 | 0 |
| 10 | 0 |
| 11 | 0 |
| 12 | 3 |
2015
| 1 | 0 |
| 2 | 5 |
| 3 | 1 |
| 4 | 1 |
| 5 | 1 |
| 6 | 1 |
| 7 | 3 |
| 8 | 3 |
| 9 | 3 |
| 10 | 0 |
| 11 | 3 |
| 12 | 0 |
2016
| 1 | 3 |
| 2 | 3 |
| 3 | 7 |
| 4 | 5 |
| 5 | 1 |
| 6 | 2 |
| 7 | 1 |
| 8 | 2 |
| 9 | 2 |
| 10 | 2 |
| 11 | 3 |
| 12 | 2 |
2017
| 1 | 0 |
| 2 | 4 |
| 3 | 3 |
| 4 | 0 |
| 5 | 2 |
| 6 | 11 |
| 7 | 2 |
| 8 | 1 |
| 9 | 1 |
| 10 | 1 |
| 11 | 0 |
| 12 | 1 |
2018
| 1 | 1 |
| 2 | 4 |
| 3 | 4 |
| 4 | 4 |
| 5 | 3 |
| 6 | 0 |
| 7 | 8 |
| 8 | 6 |
| 9 | 6 |
| 10 | 3 |
| 11 | 5 |
| 12 | 3 |
2019
| 1 | 2 |
| 2 | 3 |
| 3 | 2 |
| 4 | 1 |
| 5 | 8 |
| 6 | 3 |
| 7 | 3 |
| 8 | 0 |
| 9 | 9 |
| 10 | 3 |
| 11 | 0 |
| 12 | 8 |
2020
| 1 | 2 |
| 2 | 2 |
| 3 | 2 |
| 4 | 7 |
| 5 | 4 |
| 6 | 4 |
| 7 | 4 |
| 8 | 4 |
| 9 | 6 |
| 10 | 5 |
| 11 | 11 |
| 12 | 11 |
2021
| 1 | 7 |
| 2 | 5 |
| 3 | 7 |
| 4 | 5 |
| 5 | 7 |
| 6 | 9 |
| 7 | 4 |
| 8 | 7 |
| 9 | 6 |
| 10 | 8 |
| 11 | 9 |
| 12 | 8 |
2022
| 1 | 21 |
| 2 | 18 |
| 3 | 12 |
| 4 | 4 |
| 5 | 6 |
| 6 | 8 |
| 7 | 3 |
| 8 | 6 |
| 9 | 1 |
| 10 | 8 |
| 11 | 5 |
| 12 | 8 |
2023
| 1 | 5 |
| 2 | 6 |
| 3 | 9 |
| 4 | 6 |
| 5 | 4 |
| 6 | 2 |
| 7 | 3 |
| 8 | 3 |
| 9 | 4 |
| 10 | 3 |
| 11 | 2 |
| 12 | 3 |
2024
| 1 | 1 |
| 2 | 4 |
| 3 | 3 |
| 4 | 1 |
| 5 | 0 |
| 6 | 0 |
| 7 | 0 |
| 8 | 0 |
| 9 | 0 |
| 10 | 0 |
| 11 | 0 |
| 12 | 0 |
